Trial Profile
A Randomized Phase II Multicenter, Open-Label Study Evaluating the Efficacy and Safety of IMAB362 in Combination With the EOX (Epirubicin, Oxaliplatin, Capecitabine) Regimen as First-Line Treatment of Patients With CLDN18.2-Positive Advanced Adenocarcinomas of the Stomach, the Esophagus or the Gastroesophageal Junction
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Zolbetuximab (Primary) ; Capecitabine; Epirubicin; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms FAST
- Sponsors Astellas Pharma Global Development; Ganymed Pharmaceuticals
- 18 Feb 2021 Protocol was amended to add a third exploratory arm to evaluate a higher dose of zolbetuximab (1000 mg/m2) combined with EOX.
- 18 Feb 2021 Results published in the Annals of Oncology
- 20 Feb 2019 Status changed from active, no longer recruiting to completed.